<DOC>
	<DOC>NCT00109278</DOC>
	<brief_summary>The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).</brief_summary>
	<brief_title>A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 6 weeks.</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy children 12 to 18 months of age. Previous receipt of measles, mumps, rubella and/or varicella vaccine. Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster. Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy. History of seizures (convulsions) Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin. A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F [37.5° C]).</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention of Measles</keyword>
</DOC>